The Short Version
Mostly True. Clinical research and patient data consistently show that Ozempic (semaglutide) use is associated with changes in taste perception — roughly one in five users report heightened sweet or salty sensitivity, supported by studies documenting altered tongue gene expression and brain responses. The "reduced enjoyment of eating" component is less rigorously established, relying more on patient reports and media accounts than controlled hedonic measurements, but it is not unsupported. The claim is directionally accurate but somewhat overstates the enjoyment dimension.